The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Alliance/CALGB 80802: Impact of hepatitis C (HCV) on doxorubicin (DO) + sorafenib (S) versus S in patients (pts) with advanced hepatocellular carcinoma (aHCC).
 
Imane H. El Dika
Consulting or Advisory Role - QED Therapeutics
Travel, Accommodations, Expenses - QED Therapeutics
 
Susan Michelle Geyer
Research Funding - Bristol-Myers Squibb (Inst)
 
Andrew B. Nixon
Consulting or Advisory Role - GlaxoSmithKline; Kanghong Pharma; Leap Therapeutics; Lilly; Promega
Research Funding - AstraZeneca/MedImmune (Inst); Eureka Therapeutics (Inst); Genentech/Roche (Inst); HTG Molecular Diagnostics (Inst); Leadiant Biosciences (Inst); medpacto (Inst); OncoMed (Inst); Promega (Inst); Seagen (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Patent (Inst); Patent Pending (Inst)
 
Federico Innocenti
Consulting or Advisory Role - Emerald Lake Safety; Symberix
Patents, Royalties, Other Intellectual Property - United States Patent: "Flavopiridol drug combinations and methods with reduced side effects", Ratain MJ, Innocenti F, Iyer L. Filed on April 12, 2001, serial number 09/835,082.; United States Patent: “Optimization of cancer treatment with irinotecan”, Ratain MJ, Innocenti F, Karabatsos P, Grimsley C, Di Rienzo A. Filed on February 12, 2003, serial number 60/446,942.; United States Provisional Application ”Methods of identifying risk of bevacizumab-induced proteinuria and hypertension”, Innocenti F, Quintanilha J, Lin D, Owzar K, Wang J. Filed on September 20, 2019, serial number 62/903,442.
 
Qian Shi
Stock and Other Ownership Interests - Amgen; Johnson & Johnson; Merck
Consulting or Advisory Role - Boehringer Ingelheim; Yiviva
Research Funding - Celgene (Inst); Roche/Genentech (Inst)
 
Sawyer B. Jacobson
No Relationships to Disclose
 
Amin Yaqubie
No Relationships to Disclose
 
Juan C. Lopez
Stock and Other Ownership Interests - Abbott; Danaher; Moderna Therapeutics; Pfizer; Roche
 
Binhui Huang
No Relationships to Disclose
 
Yi-Wei Tang
Employment - Cepheid/Danaher
Leadership - Cepheid/Danaher
Stock and Other Ownership Interests - Cepheid/Danaher
 
Yujia Wen
No Relationships to Disclose
 
Lawrence Howard Schwartz
Consulting or Advisory Role - Novartis; Regeneron
Research Funding - Boehringer Ingelheim (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Varian Medical Systems
 
Monica M. Bertagnolli
Research Funding - Abbvie (Inst); Agenus (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Baxalta (Inst); Bayer Health (Inst); Breast Cancer Research Foundation (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Chinese Medical Education Association (Inst); Complion (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); GHI Pharma (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen (Inst); Jazz Pharmaceuticals (Inst); Leidos (Inst); Leidos (Inst); Lexicon (Inst); Lilly (Inst); Massachusetts General Hospital (Inst); Matrex (Inst); Mayo Clinic (Inst); Merck (Inst); Merck (Inst); Millenium Pharamceuticals (Inst); MITRE Corporation (Inst); Novartis (Inst); Patient-Centered Outcomes Research Institute (PCORI) (Inst); Pfizer (Inst); Pharmacyclics (Inst); Robert Wood Johnson Foundation (Inst); Sagerock Advisors (Inst); Sanofi (Inst); SERVIER (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); Teva (Inst)
(OPTIONAL) Uncompensated Relationships - Leap Therapeutics; Syntalogic Pharmaceuticals; Syntimmune
 
Jeffrey A. Meyerhardt
Honoraria - Cota Healthcare; Taiho Pharmaceutical
Consulting or Advisory Role - Array BioPharma
Research Funding - Boston Biomedical (Inst)
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Agios (I); AstraZeneca (I); Autem Medical (I); Bayer (I); BeiGene (I); Berry Genomics (I); Celgene (I); CytomX Therapeutics; Debiopharm Group (I); Eisai (I); Exelixis/Ipsen (I); Flatiron Health (I); Genentech/Roche (I); Gilead Sciences (I); Incyte (I); Ipsen (I); Janssen; LAM Therapeutics (I); Lilly (I); Loxo; Merck; Minapharma (I); QED Therapeutics (I); RedHill Biopharma (I); Silenseed; Sillajen (I); SOBI; TheraBionic (I); twoXAR; Vector Health (I); Yiviva (I)
Research Funding - Acta Biologica (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Halozyme (Inst); MabVax (Inst); Roche (Inst); Silenseed (Inst)
 
Alan P. Venook
Consulting or Advisory Role - Genentech; Halozyme; Merck Sharp & Dohme
Research Funding - Amgen; Bristol-Myers Squibb (Inst); Genentech/Roche (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from Now-UptoDate for authoring and maintaining two chapters
Travel, Accommodations, Expenses - Genentech; Roche
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - Agios; AstraZeneca; Autem Medical; Bayer; BeiGene; Berry Genomics; Celgene; CytomX Therapeutics (I); Eisai; Flatiron Health; Genoscience Pharma; Gilead Sciences; Gilead Sciences; Incyte; Ipsen; LAM Therapeutics; Lilly; Loxo (I); Merck Serono; Minapharma; QED Therapeutics; RedHill Biopharma; Roche/Genentech; Silenseed (I); Sillajen; SOBI (I); TheraBionic; twoXAR; Vector Health; Yiviva
Research Funding - Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Exelixis (Inst); Incyte (Inst); Polaris (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst)
Travel, Accommodations, Expenses - Polaris